Junshi Biosciences of Shanghai announced Tuoyi (toripalimab), its anti-PD-1 checkpoint inhibitor, was approved in China as a second-line treatment for melanoma, the first domestic PD-1 approved in China. There are three other China-developed anti-PD-1 mAbs under review by the NMPA. Tuoyi joins two US already-China-approved PD-1 products in the market: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. Junshi is completing a $400 million IPO on the Hong Kong Exchange.
Source: China Biotoday
